Type 1 Diabetes Mellitus: Autoimmune Mechanisms and Treatment

Mustafa Moazam

Deccan College of Medical Sciences, Hyderabad, India.

Shazain Khan

Benedictine University, Illinois, USA.

Issac Quiroga

University of Texas at El Paso, El Paso, USA.

Karen Parra

University of Texas at El Paso, El Paso, USA.

Paulina Flores

University of Texas at El Paso, El Paso, USA.

Eman Fatima

Akhtar Saeed Medical and Dental College, Lahore, Pakistan.

Andrea Amato

University of Texas at El Paso, El Paso, USA.

Syeda I. Tahera

Dow University of Health Sciences, Karachi, Pakistan.

Muhammad Sohail S. Mirza *

Shandong University School of Medicine, Jinan, China.

*Author to whom correspondence should be addressed.


Abstract

This article provides a comprehensive overview of Type 1 Diabetes Mellitus (T1DM), highlighting the autoimmune origins of the illness and its therapeutic options. It discusses the role of insulin in metabolism and highlights the fact that the autoimmune destruction of pancreatic beta cells is the primary characteristic of type 1 diabetes. Environmental triggers such as viral infections, cow's milk proteins, and insufficient vitamin D are studied in addition to genetic factors such as specific alleles associated with the disease's susceptibility. The report discusses the global epidemiology of T1DM and its increasing incidence, emphasizing the need for a comprehensive approach to treatment. Various treatment options are evaluated, emphasizing the need for customized approaches to treat this complex autoimmune disease. These options include gene therapy, insulin treatment, immunomodulatory medications, and vaccination. All things considered, the study adds to our understanding of T1DM and highlights the ongoing need to develop effective treatment modalities.

Keywords: Type 1 diabetes mellitus, autoimmune mechanisms, treatment, environmental


How to Cite

Moazam, Mustafa, Shazain Khan, Issac Quiroga, Karen Parra, Paulina Flores, Eman Fatima, Andrea Amato, Syeda I. Tahera, and Muhammad Sohail S. Mirza. 2024. “Type 1 Diabetes Mellitus: Autoimmune Mechanisms and Treatment”. Journal of Advances in Medicine and Medical Research 36 (7):142-51. https://doi.org/10.9734/jammr/2024/v36i75492.

Downloads

Download data is not yet available.

References

Mobasseri M, Shirmohammadi M, Amiri T, et al. Prevalence and incidence of type 1 diabetes in the world: A systematic review and meta-analysis. Health Promotion Perspectives. 2020;10(2):98–115. Available:https://doi.org/10.34172/hpp.2020.18

Suinyuy, Lukong Marie Chantal, Tembe Estella Fokunang, Dehayen Mesmin, Ngo Valery Ngo, Charles Ntungwen Fokunang. Evaluation of the therapeutic approach and outcome of type 2 diabetes mellitus management strategies in Cameroon. Journal of Advances in Medical and Pharmaceutical Sciences. 2019;20(4):1-15. Available:https://doi.org/10.9734/jamps/2019/v20i430115.

Nwafor, Chibuike Eze, Otonye Briggs. Pattern of arrhythmia among diabetes mellitus patients in South-South, Nigeria: 24-Hour ambulatory ECG (Holter ECG) study. Asian Journal of Medicine and Health. 2024;22(6):153-59. Available:https://doi.org/10.9734/ajmah/2024/v22i61032.

Xie Z, Chang C, Zhou Z. Molecular mechanisms in autoimmune type 1 diabetes: A critical review. Clinical Reviews in Allergy & Immunology. 2014, Oct;47: 174-92.

Krzewska A, Ben-Skowronek I. Effect of Associated Autoimmune Diseases on Type 1 Diabetes Mellitus Incidence and Metabolic Control in Children and Adolescents. BioMed Research International; 2016;2016:6219730.

Available:https://doi.org/10.1155/2016/6219730

Biondi B, Kahaly GJ, Robertson RP. Thyroid dysfunction and diabetes mellitus: Two closely associated disorders. endocrine reviews. 2019;40(3):789–824. Available:https://doi.org/10.1210/er.2018-00163

Nederstigt C, Uitbeijerse BS, Janssen LGM, et al. Associated auto-immune disease in type 1 diabetes patients: A systematic review and meta-analysis. European Journal of Endocrinology. 2019; 180(2):137–46.

Available:https://doi.org/10.1530/eje-18-0515

Volta U, Tovoli F, Caio G. Clinical and immunological features of celiac disease in patients with Type 1 diabetes mellitus. Expert Review of Gastroenterology & Hepatology. 2011;5(4):479–87. Available:https://doi.org/10.1586/egh.11.38

Kota SK, Meher LK, Jammula S, et al. Clinical profile of coexisting conditions in type 1 diabetes mellitus patients. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2012;6(2):70–6. Available:https://doi.org/10.1016/j.dsx.2012.08.006

De Block CEM, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: A clinically oriented review. The Journal of Clinical Endocrinology & Metabolism. 2008;93(2):363–71. vhttps://doi.org/10.1210/jc.2007-2134

Thomas NJ, Jones SE, Weedon MN, et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: A cross-sectional, genetically stratified survival analysis from UK Biobank. The lancet Diabetes & endocrinology. 2018; 6(2):122–9. Available:https://doi.org/10.1016/S2213-8587(17)30362-5

Harjutsalo V, Sund R, Knip M et al. Incidence of Type 1 Diabetes in Finland. JAMA. 2013;310(4):427.

Available:https://doi.org/10.1001/jama.2013.8399

Weng J, Zhou Z, Guo L, et al. Incidence of type 1 diabetes in China. 2010;13. population based study. BMJ. 2018,j5295.

Available:https://doi.org/10.1136/bmj.j5295

Redondo MJ, Jeffrey J, Fain PR, et al. Concordance for islet autoimmunity among monozygotic twins. New England Journal of Medicine. 2008;359(26):2849–50. Available:https://doi.org/10.1056/nejmc0805398

Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. New England Journal of Medicine. 2017; 376(15):1419–29. Available:https://doi.org/10.1056/nejmoa1610187

Patterson CC, Harjutsalo V, Rosenbauer J, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25year period 1989–2013: A multicentre prospective registration study. Diabetologia. 2018; 62(3):408–17. Available:https://doi.org/10.1007/s00125-018-4763-3

Johnson MB, Hattersley AT, Flanagan SE. Monogenic autoimmune diseases of the endocrine system. The Lancet Diabetes & Endocrinology. 2016;4(10): 862–72. Available:https://doi.org/10.1016/s2213-8587(16)30095-x

Abbasi J. Teplizumab improves beta cell function, delays type 1 diabetes. JAMA. 2021;325(14):1385.

Available:https://doi.org/10.1001/jama.2021.4628

Redondo MJ, Rewers M, Yu L, et al. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: Prospective twin study. BMJ. 1999;318(7185):698– 702.

Available:https://doi.org/10.1136/bmj.318.7185.698

Morahan G. Insights into type 1 diabetes provided by genetic analyses. Current Opinion in Endocrinology & Diabetes and Obesity. 2012;19(4):263– 70. Available:https://doi.org/10.1097/med.0b013e328355b7fe

Atkinson MA, Maclaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes. 1990;39(8):933–7. Available:https://doi.org/10.2337/diab.39.8.933

Bennett and ST, Todd JA. Human type 1 diabetes and the insulin gene: Principles of mapping polygenes. Annual Review of Genetics. 1996;30 (1):343–70. Available:https://doi.org/10.1146/annurev.genet.30.1.343

Vafiadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nature Genetics. 1997; 15(3):289–92. Available:https://doi.org/10.1038/ng0397-289

Larsen Zm, Kristiansen Op, Mato E, et al. IDDM12 (CTLA4) on 2q33 andIDDM13on 2q34 in Genetic Susceptibility to Type 1 Diabetes (Insulin-dependent). Autoimmunity. 1999;31(1):35–42.

Available:https://doi.org/10.3109/08916939908993857

Vella A, Cooper JD, Lowe CE, et al. Localization of a type 1 diabetes locus in the il2ra/cd25 region by use of tag single-nucleotide polymorphisms. The American Journal of Human Genetics. 2005;76(5): 773–9.

Available:https://doi.org/10.1086/429843

Hyote H, Taylor KW. The role of viruses in human diabetes. Diabetologia. 2002; 45(10):1353–61. Available:https://doi.org/10.1007/s00125-002-0852-3

Nigro G, Pacella ME, Patanè E, et al. Multi-system coxsackievirus B-6 infection with findings suggestive of diabetes mellitus. European Journal of Pediatrics. 1986;145(6):557–9. Available:https://doi.org/10.1007/BF02429065

Robles DT, Eisenbarth GS. Type 1A diabetes induced by infection and immunization. Journal of Autoimmunity. 2001;16(3):355–62. Available:https://doi.org/10.1006/jaut.2000.0483

Rubinstein P, Walker ME, Fedun B, et al. The HLA system in congenital rubella patients with and without diabetes. Diabetes. 1982;31(12):1088– 91. Available:https://doi.org/10.2337/diacare.31.12.1088

Norris JM. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA. 2003;290(13):1713.

Available:https://doi.org/10.1001/jama.290.13.171

Norris JM, Yin X, Lamb MM, et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA. 2007; 298(12):1420. Available:https://doi.org/10.1001/jama.298.12.1420

Myers MA, Kalindi Hettiarachchi, Justin Peter Ludeman,et al. Dietary microbial toxins and type 1 diabetes. Annals of the New York Academy of Sciences. 2003; 1005(1):418–22. Available:https://doi.org/10.1196/annals.1288.071

Hviid A, Stellfeld M, Wohlfahrt J, et al. Childhood vaccination and type 1 diabetes. New England Journal of Medicine. 2004; 350(14):1398–404. Available:https://doi.org/10.1056/nejmoa03266

Beyan H, Valorani MG, Pozzilli P. –to: Gale EAM. A missing link in the hygiene hypothesis? Diabetologia 45:588–592. Diabetologia. 2003;46(2):301–2. Available:https://doi.org/10.1007/s00125-002-1019-y

Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. New England Journal of Medicine. 2002;347(12):911–20. Available:https://doi.org/10.1056/nejmra020100

Chase HP, Butler-Simon N, Garg SK, et al. Cyclosporine a for the treatment of new-onset insulin-dependent diabetes mellitus. Pediatrics. 1990;85(3):241–5. Available:https://doi.org/10.1542/peds.85.3.241

Cook J, Hudson IL, Harrison LC, et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type i diabetes. Diabetes. 1989; 38(6):779–83. Available:https://doi.org/10.2337/diab.38.6.779

Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. The New England Journal of Medicine. 2005;352(25):2598–608. Available:https://doi.org/10.1056/NEJMoa043980

Skelley JW, Elmore LK, Kyle JA. Teplizumab for treatment of type 1 diabetes mellitus. Annals of Pharmacotherapy. 2012;46(10):1405–12. Available:https://doi.org/10.1345/aph.1r065

Muir A, Peck AB, Clare-Salzler MJ, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. Journal of Clinical Investigation. 1995;95(2):628–34. Available:https://doi.org/10.1172/jci117707

Zhang ZP, Davidson L, Eisenbarth GS, et al. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. 1991; 88(22):10252–6. Available:https://doi.org/10.1073/pnas.88.22.10252

Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). 1996;93(2): 956–60. Available:https://doi.org/10.1073/pnas.93.2.956

Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care. 2013;37(1):9–16. Available:https://doi.org/10.2337/dc13-2112

Galli-Tsinopoulou A, Stergidou D. Insulin analogues for type 1 diabetes in children and adolescents. Drugs of Today. 2012; 48(12):795. Available:https://doi.org/10.1358/dot.2012.48.12.1872944

Vella A, Cooper JD, Lowe CE, et al. Localization of a type 1 diabetes locus in the il2ra/cd25 region by use of tag single-nucleotide polymorphisms. The American Journal of Human Genetics. 2005;76(5): 773–9.

Available:https://doi.org/10.1086/429843

Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine. 2000;343(4):230–8.

Available:https://doi.org/10.1056/nejm200007273430401

Ito A, Nobuyoshi Aoyanagi, Maki T. Regulation of autoimmune diabetes by interleukin 3-dependent bone marrow-derived cells in NOD mice. Journal of autoimmunity. 1997;10(4): 331–8. Available:https://doi.org/10.1006/jaut.1997.0142

Creusot RJ, C. Garrison Fathman. Gene therapy for type 1 diabetes: A novel approach for targeted treatment of autoimmunity. Journal of Clinical Investigation. 2004;114(7):892–4. Available:https://doi.org/10.1172/jci23168

BarcalaTabarrozzi AE, Castro CN, Dewey RA, et al. Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus. Clinical and Experimental Immunology. 2013;171(2):135–46. Available:https://doi.org/10.1111/cei.12019